Covalent targeting of non-cysteine residues in PI4KIIIβ-Reference-Cited by-同舟云学术

Covalent targeting of non-cysteine residues in PI4KIIIβ

Published:2023 Issue:12 Volume:4 Page:1111-1122
ISSN:2633-0679
Container-title:RSC Chemical Biology
language:en
Short-container-title:RSC Chem. Biol.

Author:

Cosgrove Brett¹²^ORCID,Grant Emma K.¹,Bertrand Sophie¹,Down Kenneth D.¹,Somers Don O.³,P. Evans John⁴,Tomkinson Nicholas C. O.²^ORCID,Barker Michael D.¹

Affiliation:

1. Medicinal Chemistry, GlaxoSmithKline Medicines Research Centre, Stevenage, SG1 2NY, UK

2. Department of Pure and Applied Chemistry, University of Strathclyde, Glasgow, G1 1XL, UK

3. Structural and Biophysical Science, GlaxoSmithKline Medicines Research Centre, Stevenage, SG1 2NY, UK

4. Screening, Profiling and Mechanistic Biology, GlaxoSmithKline Medicines Research Centre, Stevenage, SG1 2NY, UK

Abstract

The synthesis and characterisation of fluorosulfate covalent inhibitors of the catalytic lysine, a distal tyrosine or both residues in the lipid kinase PI4KIIIβ is described.

Funder

Engineering and Physical Sciences Research Council

Publisher

Royal Society of Chemistry (RSC)

Subject

Biochemistry, Genetics and Molecular Biology (miscellaneous),Molecular Biology,Biochemistry,Chemistry (miscellaneous)

Link

http://pubs.rsc.org/en/content/articlepdf/2023/CB/D3CB00142C

Reference52 articles.

1. Projections of Global Mortality and Burden of Disease from 2002 to 2030

2. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease

3. The Lipid Kinase PI4KIIIβ Is Highly Expressed in Breast Tumors and Activates Akt in Cooperation with Rab11a

4. The resurgence of covalent drugs